“…During EMT, adherent epithelial cells lose basal-apical polarity and acquire a mesenchymal phenotype that includes enhanced migratory capacity, invasiveness, resistance to apoptosis and an increased production of extracellular matrix components [1]. Some of the hallmarks of EMT include loss of CD24 cell surface expression [2][3][4], downregulation of epithelial cytokeratins 8, 18 and 19 and E-cadherin, upregulation of vimentin, and mesenchymal transcriptional regulators such as Snai1 (Snail), Snai2 (Slug), Zeb1, Zeb2, Twist, FOXC1, and FOXC2 as reviewed in [5]. Mesenchymal cancer cells are more resistant to conventional chemotherapy and radiotherapy and correlate with tumor recurrence and a poor prognosis [6], [7].…”